1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
193.09 USD   -1.34%
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's Disease to FDA
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : to Report Fourth Quarter and Full Year 2021 Financial Results February 3, 2022

01/19/2022 | 04:26pm EDT

Cambridge, Mass.- Biogen Inc. (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2021 financial results Thursday, February 3, 2022, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen's website at investors.biogen.com. Following the live webcast, an archived version of the call will be available on the website.

About Biogen
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. Biogen is also commercializing biosimilars and focusing on advancing the industry's most diversified pipeline in neuroscience that will transform the standard of care for patients in several areas of high unmet need.

In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company's operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

Disclaimer

Biogen Inc. published this content on 19 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 January 2022 21:25:24 UTC.


© Publicnow 2022
All news about BIOGEN INC.
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Japanese shares rise on energy, financials boost
RE
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 837 M - -
Net income 2022 2 005 M - -
Net cash 2022 60,0 M - -
P/E ratio 2022 13,7x
Yield 2022 -
Capitalization 28 278 M 28 278 M -
EV / Sales 2022 2,87x
EV / Sales 2023 2,66x
Nbr of Employees 9 610
Free-Float 85,4%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 193,09 $
Average target price 245,90 $
Spread / Average Target 27,3%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-19.52%28 278
CSL LIMITED-6.06%93 171
SAMSUNG BIOLOGICS CO.,LTD.-11.85%44 721
WUXI BIOLOGICS (CAYMAN) INC.-42.79%28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-26.31%21 889
UCB-11.65%17 758